ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO693

T Regulatory Cells in Peritoneal Dialysis: Effect of the First Dialysis Session

Session Information

Category: Dialysis

  • 703 Dialysis: Peritoneal Dialysis


  • Caprara, Carlotta, IRRIV, Vicenza----, Italy
  • Sharma, Rahul, University of Virginia, Charlottesville, Virginia, United States
  • Frigo, Anna chiara, University of Padova, Padova, Italy
  • Pomare' Montin, Diego, IRRIV, Vicenza----, Italy
  • Corradi, Valentina, San Bortolo Hospital, Vicenza, Italy
  • de Cal, Massimo, San Bortolo Hospital, Vicenza, Italy
  • Ronco, Claudio, San Bortolo Hospital, Vicenza, Italy

T Regulatory (Treg) cells are a subpopulation of T cells that modulate the immune system, maintain tolerance to self-antigens, prevent autoimmune disease and regulate key immune responses across a variety of disease settings. In the literature, contrasting results have been reported about the influence of dialysis on Treg cells, in chronic kidney disease stage G5 patients that show activated but impaired immune system. Moreover the influence of dialysis on T cells needs further investigation.
The aim of this study is to evaluate the influence of the first peritoneal dialysis (PD) treatment on Treg cells subset.


A total of 13 patients that have to start PD were enrolled. Treg were studied by flow cytometry with: CD3(PerCP); CD4(FITC); CD25(PECy7); CD127(PE) and FOXP3(APC) antibodies.
Time point: T0 (before the first dialysis treatment); T1 (after 1 month).
We performed Wilcoxon for dependent samples to compare the mean delta percentage difference between T0 and T1(100*(T1-T0)/T0).


Treg cells (either considered as CD25+FoxP3+ or as Foxp3+) analyzed as percentage of lymphocytes showed a statistically significant increase during time (median=35.92; p=0.0425 for CD25+FOXP3+ and median=30.85; p=0.0479 for FOXP3+);
Splitting Foxp3+ cells into CD25Hi, CD25Int and CD25Lo, showed an increment during time of Foxp3+CD25hi population (median=53.85; p=0.0215) while the other two populations remained unchanged (median=23.81 and median=15.38 respectively; p>0.05), as well as T lymphocytes (median=-6.58; p>0.05).


The study analyzed for the first time T cells variation before and after the first PD treatment.
PD treatment improves T cells status by increasing Treg percentage, and Treg expressing CD25 after one month of treatment, while it does not influence other cells populations.